50 min
Seminar, Hosted by U.S. Food and Drug Administration
FDA Grand Rounds – Statistical Considerations for Drug Development in Rare Disease
Center for Drug Evaluation and Research, U.S. Food and Drug Administration
Recording
Abstract
Small patient populations leave researchers with limited information when planning a phase III rare disease trial. Emily Morris discusses statistical choices in trial design and how adaptive designs can address uncertainty in the available evidence.